Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis.

Anti-Bacterial Agents / therapeutic use Bacteremia / microbiology Humans Methicillin-Resistant Staphylococcus aureus Sepsis / drug therapy Staphylococcal Infections / microbiology Staphylococcus aureus
Bacteraemia Meta-analysis Mortality Staphylococcus aureus

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 11 01 2022
revised: 09 03 2022
accepted: 12 03 2022
pubmed: 28 3 2022
medline: 27 7 2022
entrez: 27 3 2022
Statut: ppublish

Résumé

Precise estimates of mortality in Staphylococcus aureus bacteraemia (SAB) are important to convey prognosis and guide the design of interventional studies. We performed a systematic review and meta-analysis to estimate all-cause mortality in SAB and explore mortality change over time. The MEDLINE and Embase databases, as well as the Cochrane Database of Systematic Reviews, were searched from January 1, 1991 to May 7, 2021. Human observational studies on patients with S. aureus bloodstream infection were included. The study analyzed data of patients with a positive blood culture for S. aureus. Two independent reviewers extracted study data and assessed risk of bias using the Newcastle-Ottawa Scale. A generalized, linear, mixed random effects model was used to pool estimates. A total of 341 studies were included, describing a total of 536,791 patients. From 2011 onward, the estimated mortality was 10.4% (95% CI, 9.0%-12.1%) at 7 days, 13.3% (95% CI, 11.1%-15.8%) at 2 weeks, 18.1% (95% CI, 16.3%-20.0%) at 1 month, 27.0% (95% CI, 21.5%-33.3%) at 3 months, and 30.2% (95% CI, 22.4%-39.3%) at 1 year. In a meta-regression model of 1-month mortality, methicillin-resistant S. aureus had a higher mortality rate (adjusted OR (aOR): 1.04; 95% CI, 1.02-1.06 per 10% increase in methicillin-resistant S. aureus proportion). Compared with prior to 2001, more recent time periods had a lower mortality rate (aOR: 0.88; 95% CI, 0.75-1.03 for 2001-2010; aOR: 0.82; 95% CI, 0.69-0.97 for 2011 onward). SAB mortality has decreased over the last 3 decades. However, more than one in four patients will die within 3 months, and continuous improvement in care remains necessary.

Sections du résumé

BACKGROUND BACKGROUND
Precise estimates of mortality in Staphylococcus aureus bacteraemia (SAB) are important to convey prognosis and guide the design of interventional studies.
OBJECTIVES OBJECTIVE
We performed a systematic review and meta-analysis to estimate all-cause mortality in SAB and explore mortality change over time.
DATA SOURCES METHODS
The MEDLINE and Embase databases, as well as the Cochrane Database of Systematic Reviews, were searched from January 1, 1991 to May 7, 2021.
STUDY ELIGIBILITY CRITERIA METHODS
Human observational studies on patients with S. aureus bloodstream infection were included.
PARTICIPANTS METHODS
The study analyzed data of patients with a positive blood culture for S. aureus.
METHODS METHODS
Two independent reviewers extracted study data and assessed risk of bias using the Newcastle-Ottawa Scale. A generalized, linear, mixed random effects model was used to pool estimates.
RESULTS RESULTS
A total of 341 studies were included, describing a total of 536,791 patients. From 2011 onward, the estimated mortality was 10.4% (95% CI, 9.0%-12.1%) at 7 days, 13.3% (95% CI, 11.1%-15.8%) at 2 weeks, 18.1% (95% CI, 16.3%-20.0%) at 1 month, 27.0% (95% CI, 21.5%-33.3%) at 3 months, and 30.2% (95% CI, 22.4%-39.3%) at 1 year. In a meta-regression model of 1-month mortality, methicillin-resistant S. aureus had a higher mortality rate (adjusted OR (aOR): 1.04; 95% CI, 1.02-1.06 per 10% increase in methicillin-resistant S. aureus proportion). Compared with prior to 2001, more recent time periods had a lower mortality rate (aOR: 0.88; 95% CI, 0.75-1.03 for 2001-2010; aOR: 0.82; 95% CI, 0.69-0.97 for 2011 onward).
CONCLUSIONS CONCLUSIONS
SAB mortality has decreased over the last 3 decades. However, more than one in four patients will die within 3 months, and continuous improvement in care remains necessary.

Identifiants

DOI: 10.1016/j.cmi.2022.03.015 PMID: 35339678
pubmed: 35339678
pii: S1198-743X(22)00154-9
doi: 10.1016/j.cmi.2022.03.015
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076-1084

Informations de copyright

Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Anthony D Bai (AD)

Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Electronic address: anthony.bai@queensu.ca.

Carson K L Lo (CKL)

Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Adam S Komorowski (AS)

Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Division of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Mallika Suresh (M)

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Kevin Guo (K)

Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Akhil Garg (A)

Department of Medicine, Queen's University, Kingston, Ontario, Canada.

Pranav Tandon (P)

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Julien Senecal (J)

Faculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.

Olivier Del Corpo (O)

Department of Medicine, Division of Experimental Medicine, Division of Infectious Diseases, McGill University, Montréal, Quebec, Canada.

Isabella Stefanova (I)

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Clare Fogarty (C)

McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Guillaume Butler-Laporte (G)

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada.

Emily G McDonald (EG)

Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Matthew P Cheng (MP)

Division of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montréal, Quebec, Canada.

Andrew M Morris (AM)

Division of Infectious Diseases, Department of Medicine, Sinai Health, University Health Network, University of Toronto, Toronto, Canada.

Mark Loeb (M)

Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Todd C Lee (TC)

McGill University Health Centre, McGill University, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Bactériémie › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus résistant à la méticilline › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à staphylocoques › Staphylococcus aureus bacteraemia mortality: a...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus bacteraemia mortality: a...